Genzyme's Lemtrada gins positive PhIII MS data; Apixaban fails to cut risk of blood clots; Diabetes epidemic metastasizes;

 @FierceBiotech: BGI, Children's Hospital of Philadelphia team on next-gen sequencing, bioinformatics. Report | Follow @FierceBiotech

 @JohnCFierce: Splitsville for Athersys and Angiotech on stem cell program; Athersys inks $20M stock purchase deal. | Follow @JohnCFierce

 @RyanMFierce: Open R&D biotech model makes sense in researching PTSD. We owe it to veterans with psych scars to team up here.Article | Follow @RyanMFierce

> Genzyme is reporting a fresh set of positive data for its MS drug Lemtrada, moving it another step closer to an FDA approval. The data demonstrated a 49% cut in relapse rates and a 42% drop in the worsening of MS-related disability, compared to Rebif, according to a story in MassHighTech. Report

> A new study has failed to help Bristol-Myers Squibb and Pfizer make a case for apixaban as an effective new protection against blood clots in the legs and lungs of patients following hospitalization. Clots appeared in 2.7 percent of patients given apixaban, compared to the 3.1 percent offered the standard Lovenox. The results weren't a big surprise for analysts though, especially after Xarelto failed a similar study. Report

> Athersys is reporting today that its partner Angiotech has dropped out of their partnership to develop a new stem cell treatment for heart attack patients. Simultaneously the biotech also announced that Aspire Capital Fund had agreed to buy up to $20 million worth of the company's shares. Report

> Aastrom Biosciences says that final data from a mid-stage study of its personalized cellular treatment demonstrated that it had helped restore damaged tissue in the legs of patients with blocked arteries. Story

> IntelGenx has won FDA approval of its high-dose version of the antidepressant Wellbutrin, CPI-300. Release

Pharma News

 @FiercePharma: Pfizer's Lipitor hardball, from the NYT. The gist: Discounts for PBMs that block generic versions. Article | Follow @FiercePharma

> J&J, Bayer can celebrate with ACS data on Xarelto. Report

> No new cost-cutting, Roche chairman pledges. Item

> Pfizer's Lipitor survival strategy under attack. News

Medical Device News

> Report: S&N to raise R&D budget. Item

> OrbusNeich releases data on combo stent, Genous. Report

> Stryker to cut 5% of workforce. Article

<Biotech IT News

> Dell puts cloud-computing muscle behind personalized cancer trial. Report

> BGI, Children's Hospital of Philadelphia team on next-gen sequencing, bioinformatics. Article

> Foldit strategies uncovered, spotlights open R&D breakthrough. News

> Y Combinator alum Comprehend lands $1.2M seed round for clinical data analytics. Story

And Finally... A new study finds that diabetes will affect one in 10 adults by 2030, interfering with the country's economic development. Story

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.